Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term nucleos(t)ide analogues and hepatic steatosis in chronic hepatitis B
ChiCTR2200061728Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide in Chronic Hepatitis B (CHB) (3 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Hepatic function, Blood lipids and 3 more. Started Jul 2022; status: recruiting.
02
Drugs
entecavirtenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200061728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061728.